Elypta raises $21 million Series A to develop metabolism-based multi-cancer early detection test
Stockholm, June 20, 2022: Elypta, a Swedish diagnostics company aiming to commercialize the first metabolism-based liquid biopsy for early detection of any cancer, today announced the raise of $21 million in a series A financing round led by Bonnier Ventures.- The series A is a pivotal moment for Elypta as it fully funds the development of our two leading indications, says Karl Bergman, CEO at Elypta. The company will use the capital to develop and validate blood and urine tests for Multi-Cancer Early Detection (MCED) in adults with no symptoms of cancer and for detection of recurrence